Ethicon Recognized for Innovation by Prominent International Design Society

Views tracker viewed for user 71270
Johnson and Johnson's picture
Printer-friendly versionPrinter-friendly version

ENSEAL® G2 Articulating Tissue Sealers receives Bronze International Design Excellence Awards (IDEA) from the Industrial Designers Society of America (IDSA)

CINCINNATI, OH – (July 2, 2014) – Ethicon Endo-Surgery (Ethicon) today announced the receipt of a Bronze International Design Excellence Awards (IDEA) from the Industrial Designers Society of America (IDSA) for innovation with ENSEAL® G2 Articulating Tissue Sealers.

At Ethicon our commitment to delivering strategic design and consistent value is a team process, driven by observational insights, procedural knowledge and the ultimate goal of positively impacting patient outcomes,” said Steve Eichmann, Director of Research & Development, Industrial Design and Human Factors. “We appreciate this recognition from IDSA for our customer-driven innovation and the advancements that ENSEAL® G2 Articulating Tissue Sealers represent for both patients and healthcare providers.”

The IDSA recognized the ENSEAL® G2 Articulating Tissue Sealers for an innovative design that enables surgeons to access tissue in deep or tight spaces as well as maneuver around corners and behind structures in the body. This is the first articulating advanced energy device of its kind that enables surgeons to use a perpendicular approach to cut and seal vessels up to 7mm in diameter and lymphatics through a 5mm port. A flexible joint articulates 55 degrees on either side (for a total 110 degrees of articulation) without sacrificing shaft stiffness, while an articulation wheel enables users to lock the desired angle of approach into position for stability.

As a Bronze Medal Winner, ENSEAL® G2 Articulating Tissue Sealers will be featured in the IDEA 2014 Web Gallery, in IDSA’s Innovation Magazine’s Fall Yearbook of Design Excellence, as well as through various design media outlets. As one of IDEA’s winning designs, ENSEAL® G2 Articulating Tissue Sealers will also be added to the exhibition at The Henry Ford Museum to share and preserve the story of American innovation.                          

About the IDSA and the IDEA Competition
Founded in 1965, the Industrial Designers Society of America (IDSA) is the world’s oldest and largest member-driven society for industrial design. The society’s flagship program is its IDEA competition. It also hosts the International Design Conference and five regional conferences each year and publishes Innovation, a quarterly journal focused on industrial design. IDSA has more than 3,200 members in 30 professional chapters in the US and internationally.         

About Our Company
Ethicon, Inc. and Ethicon Endo-Surgery, Inc., two companies with long histories of medical innovation, do business under the Ethicon brand. Their surgical technologies and products (including sutures, staplers, energy devices, clip appliers, trocars and meshes) are used around the world to treat colorectal and thoracic conditions, women’s health conditions, hernias, cancer and obesity. Ethicon, Inc. and Ethicon Endo-Surgery, Inc. are part of the Johnson & Johnson Family of Companies. Learn more at www.ethicon.com, and follow us on Twitter .

News Source : Ethicon Recognized for Innovation by Prominent International Design Society
Copy this html code to your website/blog to embed this press release.

Johnson and Johnson Press Release

Post date
03/14/2016 - 22:20 First Real-World Evidence Comparing an SGLT2 Inhibitor with DPP-4 Inhibitors Shows Adults with Type 2 Diabetes Achieve Greater Blood Glucose Control with INVOKANA
03/07/2016 - 18:17 Ethicon Announces Agreement To Acquire NeuWave Medical, Inc.
03/04/2016 - 10:26 Real-World Study Found XARELTO
03/02/2016 - 18:38 DePuy Synthes Companies Announces New Strategic Alliance with Experts in Bundled Payments
03/01/2016 - 18:02 LifeScan Announces Strategic Collaboration with WellDoc Corporation to Advance Mobile Care Solutions for Type 2 Diabetes Patients
03/01/2016 - 08:45 Johnson & Johnson Innovation Unveils JLABS @ TMC to Help Catalyze Early Stage Research through to Commercialization for Healthcare Solutions in Houston
02/23/2016 - 12:45 New Onetouch Verio Flex Blood Glucose Monitoring System with ColorSure Technology Takes the Guesswork Out of Blood Sugar Test Results
02/22/2016 - 14:03 First Regimen Combining Long Acting Injectable Antiretrovirals; 32-Week LATTE 2 Study Results Presented at CROI
02/17/2016 - 10:27 Johnson & Johnson Issues Call for Innovative Ideas to Reduce HIV Infections in Sub-Saharan Africa
02/08/2016 - 17:47 RHINOCORT Allergy Spray Now Available Over The Counter Nationally
01/20/2016 - 08:39 Johnson & Johnson Joins First Industry-wide Call for New Collective Action to Address Antimicrobial Resistance
01/19/2016 - 08:42 Johnson & Johnson Announces Actions to Strengthen Medical Devices Leadership Position in Evolving Healthcare Marketplace
01/11/2016 - 01:47 FDA Approves Animas ® Vibe ® Insulin Pump and Continuous Glucose Monitoring System For Use in Children
01/08/2016 - 05:29 Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. Announce Agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. to Develop and Commercialize Curative Treatments for Hepatitis B
01/06/2016 - 03:24 Johnson & Johnson Health and Wellness Solutions Teams with Plug and Play to Launch Health and Wellness Technology Accelerator
01/06/2016 - 03:13 Johnson & Johnson Partners with Leading Universities to Advance Women’s Education in Science, Technology, Engineering, Math, Manufacturing and Design (STEM2D)
12/18/2015 - 02:07 Janssen Announces Collaboration with Bavarian Nordic to Develop Vaccine for Chronic Human Papillomavirus (HPV) Infections
12/14/2015 - 19:29 Janssen announces collaboration with FIND to transform access to diagnostics and therapeutic solutions for TB and MDR-TB
12/09/2015 - 18:32 Johnson & Johnson Announces Formation of Verb Surgical Inc., In Collaboration With Verily
12/07/2015 - 20:12 First Data Unveiled from CALLISTO Program Examining the Use of XARELTO ® (rivaroxaban) for Treating Blood Clots in People with Cancer
Copy and paste this code to display this page on your website .
Syndicate content